TOKYO, Apr 25, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu and the Southern Tohoku General Hospital today announced the launch of a joint research project with Fujitsu Japan Limited (hereinafter Fujitsu Japan)(1) and FCOM CORPORATION (hereinafter FCOM)(2) on an AI technology for the early detection of pancreatic cancer from […]

TOKYO, Mar 7, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data. Leveraging the world’s fastest supercomputer “Fugaku,”(1) the new technology […]

TOKYO, JAPAN and WALTHAM, Mass., Dec 15, 2021 – (JCN Newswire via SEAPRWire.com) – BostonGene Corporation and NEC Corporation (TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer new windowBostonGene Tumor Portrait Tests in key international markets, including Japan as the first market […]

TOKYO, Dec 6, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, “eribulin”), MORAb-202, an antibody drug conjugate (ADC), and H3B-6545 (selective estrogen alpha […]

HONG KONG, Jul 6, 2021 – (ACN Newswire via SEAPRWire.com) – ACT Genomics Co. Ltd. (“ACT Genomics” or “the Group”) has completed the acquisition of MC Diagnostics Ltd. (“MCD”), a specialist molecular diagnostic company based in the United Kingdom, which marks the Group’s entry into the European precision medicine market. […]

TOKYO, Apr 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., (known as MSD outside the United States and Canada) announced today an application submission in Japan for the additional indication of Eisai’s in-house discovered […]

TOKYO, Mar 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of […]

TOKYO, Mar 12, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has received orphan drug designation for LENVIMA (generic name: lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective indication for uterine body cancer, by the Ministry of […]